{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:53:54Z","timestamp":1781636034682,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Buprenorphine is an effective medication for treating opioid use disorder but is underutilized partly due to patient apprehensiveness of the severe withdrawal symptoms it can induce when started, particularly by fentanyl-dependent individuals. An emerging facilitator to buprenorphine initiation is ketamine, a dissociative anesthetic shown to reverse opioid withdrawal symptoms in case reports and small series. A 24-hour behavioral health crisis center implemented a quality improvement protocol to address difficulties transitioning patients from fentanyl to buprenorphine using a high-dose buprenorphine initiation strategy premedicated with a low, sub-dissociative dose of intramuscular ketamine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Crisis center personnel injected ketamine 10\u2009mg intramuscularly at a cost of $0.44 per patient and 30\u2009minutes later administered buprenorphine 8\u2009mg sublingually to patients who self-reported recent use of fentanyl and were in at least moderate withdrawal. They assessed Clinical Opiate Withdrawal Scale (COWS) scores at baseline, 30\u2009minutes after ketamine, and 30\u2009minutes after buprenorphine. They compared length of stay (LOS) between patients initiating buprenorphine before and after implementing the protocol. They recorded pharmacy dispensing of buprenorphine prescriptions and follow-up visits within 30\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 50 patients treated over 13\u2009months, average COWS score dropped from 13.6 (range 8\u201321, SD 2.9) at baseline to 6.2 (range 0\u201317, SD 3.6) 30\u2009minutes after ketamine and 4.1 (range 0\u201318, SD 4.0) 30\u2009minutes after buprenorphine. Both decreases were statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) with very large effect sizes. Of the 50 patients, 36 (72%) experienced a decrease in COWS score including 27\/50 (54%) with COWS score 0\u20133 by 30\u2009minutes after buprenorphine. After protocol implementation, median LOS decreased from 66.0\u2009hours (range 20\u2013135) in the pre-protocol comparison sample to 7.0\u2009hours (range 2\u2013148) in the post-protocol sample. Patients reported no adverse effects of ketamine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this observational study, sub-dissociative dose intramuscular ketamine was a well-tolerated and inexpensive premedication for a high-dose buprenorphine initiation strategy. Most patients had rapid reduction in signs of fentanyl withdrawal after ketamine, and half had nearly complete resolution following buprenorphine. Ketamine may be a useful adjunct to increase buprenorphine uptake and reduce overdose deaths. Prospective research is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00649-3","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:04:13Z","timestamp":1770829453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study"],"prefix":"10.1186","volume":"21","author":[{"given":"J. Luke","family":"Engeriser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Chavers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda A.","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"649_CR1","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. Published 2017 Apr 26. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ"},{"issue":"2","key":"649_CR2","doi-asserted-by":"publisher","first-page":"CD002207","DOI":"10.1002\/14651858.CD002207.pub4","volume":"2014","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2):CD002207. Published 2014 Feb 6. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"649_CR3","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.5811\/westjem.2021.6.51306","volume":"22","author":"T Le","year":"2021","unstructured":"Le T, Cordial P, Sankoe M, et al. Healthcare use after buprenorphine prescription in a community emergency department: a cohort study. West J Emerg Med. 2021;22(6):1270\u201375. Published 2021 Sep 24. doi: https:\/\/doi.org\/10.5811\/westjem.2021.6.51306.","journal-title":"West J Emerg Med"},{"issue":"4","key":"649_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","volume":"46","author":"J Tkacz","year":"2014","unstructured":"Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456\u201362. https:\/\/doi.org\/10.1016\/j.jsat.2013.10.014.","journal-title":"J Subst Abuse Treat"},{"key":"649_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","volume":"74","author":"SM Silverstein","year":"2019","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. \u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76\u201383. https:\/\/doi.org\/10.1016\/j.drugpo.2019.09.003.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"649_CR6","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","volume":"16","author":"NB Varshneya","year":"2022","unstructured":"Varshneya NB, Thakrar AP, Hobelmann JG, Dunn KE, Huhn AS. Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med. 2022;16(4):e265\u201368. https:\/\/doi.org\/10.1097\/ADM.0000000000000922.","journal-title":"J Addict Med"},{"issue":"2","key":"649_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/dar.13394","volume":"41","author":"D Shearer","year":"2022","unstructured":"Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series. Drug Alcohol Rev. 2022;41(2):444\u201348. https:\/\/doi.org\/10.1111\/dar.13394.","journal-title":"Drug Alcohol Rev"},{"key":"649_CR8","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment improvement protocol (TIP) series No. 63. HHS publication No. PEP21-02-01-002. Substance abuse and mental health services administration. 2021. https:\/\/store.samhsa.gov\/product\/tip-63-medications-opioid-use-disorder\/pep21-02-01-002."},{"issue":"5","key":"649_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11.032","volume":"73","author":"AA Herring","year":"2019","unstructured":"Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73(5):481\u201387. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.11.032.","journal-title":"Ann Emerg Med"},{"key":"649_CR10","doi-asserted-by":"publisher","first-page":"111400","DOI":"10.1016\/j.drugalcdep.2024.111400","volume":"262","author":"E Bruzelius","year":"2024","unstructured":"Bruzelius E, Palamar JJ, Fitzgerald ND, Cottler LB, Carr TC, Martins SS. Law enforcement fentanyl seizures and overdose mortality in US counties, 2013-2020. Drug Alcohol Depend. 2024;262:111400. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111400.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"649_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/ADM.0000000000001395","volume":"19","author":"A Sharma","year":"2025","unstructured":"Sharma A, Dunn KE, Schmid-Doyle K, et al. Examining the severity and progression of illicitly manufactured fentanyl withdrawal: a quasi-experimental comparison. J Addict Med. 2025;19(2):172\u201378. https:\/\/doi.org\/10.1097\/ADM.0000000000001395.","journal-title":"J Addict Med"},{"issue":"6","key":"649_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","volume":"80","author":"MK Greenwald","year":"2022","unstructured":"Greenwald MK, Herring AA, Perrone J, Nelson LS, Azar P. A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med. 2022;80(6):509\u201324. https:\/\/doi.org\/10.1016\/j.annemergmed.2022.05.032.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"649_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","volume":"16","author":"KL Sue","year":"2022","unstructured":"Sue KL, Cohen S, Tilley J, Yocheved A. A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era. J Addict Med. 2022;16(4):389\u201391. https:\/\/doi.org\/10.1097\/ADM.0000000000000952.","journal-title":"J Addict Med"},{"issue":"6","key":"649_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","volume":"17","author":"MB Weimer","year":"2023","unstructured":"Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med. 2023;17(6):632\u201339. https:\/\/doi.org\/10.1097\/ADM.0000000000001202.","journal-title":"J Addict Med"},{"key":"649_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/SAR.S109919","volume":"7","author":"R H\u00e4mmig","year":"2016","unstructured":"H\u00e4mmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99\u2013105. https:\/\/doi.org\/10.2147\/SAR.S109919. Published 2016 Jul 20.","journal-title":"Subst Abuse Rehabil"},{"issue":"7","key":"649_CR16","doi-asserted-by":"publisher","first-page":"e2117128","DOI":"10.1001\/jamanetworkopen.2021.17128","volume":"4","author":"AA Herring","year":"2021","unstructured":"Herring AA, Vosooghi AA, Luftig J, et al. High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Netw Open. 2021;4(7):e2117128. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.17128. Published 2021 Jul 1.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"649_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/00952990.2022.2106574","volume":"49","author":"H Hassman","year":"2023","unstructured":"Hassman H, Strafford S, Shinde SN, Heath A, Boyett B, Dobbins RL. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection. Am J Drug Alcohol Abuse. 2023;49(1):43\u201352. https:\/\/doi.org\/10.1080\/00952990.2022.2106574.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"8","key":"649_CR18","doi-asserted-by":"publisher","first-page":"e2527016","DOI":"10.1001\/jamanetworkopen.2025.27016","volume":"8","author":"RC Waters","year":"2025","unstructured":"Waters RC, Hoog J, Bell C, et al. Injectable-only overlapping buprenorphine starting protocol in a low-threshold setting. JAMA Netw Open. 2025;8(8):e2527016. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27016. Published 2025 Aug 1.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"649_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.annemergmed.2019.01.006","volume":"74","author":"RH Phillips","year":"2019","unstructured":"Phillips RH, Salzman M, Haroz R, Rafeq R, Mazzarelli AJ, Pelletier-Bui A. Elective naloxone-induced opioid withdrawal for rapid initiation of medication-assisted treatment of opioid use disorder. Ann Emerg Med. 2019;74(3):430\u201332. https:\/\/doi.org\/10.1016\/j.annemergmed.2019.01.006.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"649_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/ADM.0000000000001073","volume":"17","author":"A Randall","year":"2023","unstructured":"Randall A, Hull I, Martin SA. Enhancing patient choice: using self-administered intranasal naloxone for novel rapid buprenorphine initiation. J Addict Med. 2023;17(2):237\u201340. https:\/\/doi.org\/10.1097\/ADM.0000000000001073.","journal-title":"J Addict Med"},{"issue":"1","key":"649_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13722-025-00555-0","volume":"20","author":"BE Williams","year":"2025","unstructured":"Williams BE, Martin SA, Hoffman KA, Andrus MD, Dellabough-Gormley E, Buchheit BM. \u201cIt\u2019s within your own power\u201d: shared decision-making to support transitions to buprenorphine. Addict Sci Clin Pract. 2025;20(1):22. https:\/\/doi.org\/10.1186\/s13722-025-00555-0. Published 2025 Mar 7.","journal-title":"Addict Sci Clin Pract"},{"issue":"11","key":"649_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","volume":"9","author":"SY Smith-Apeldoorn","year":"2022","unstructured":"Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907\u201321. https:\/\/doi.org\/10.1016\/S2215-0366(22)00317-0.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"649_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/AAP.0000000000000806","volume":"43","author":"ES Schwenk","year":"2018","unstructured":"Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine Infusions for acute pain management from the American society of regional anesthesia and pain medicine, the American academy of pain medicine, and the American society of anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456\u201366. https:\/\/doi.org\/10.1097\/AAP.0000000000000806.","journal-title":"Reg Anesth Pain Med"},{"issue":"5","key":"649_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/AAP.0000000000000808","volume":"43","author":"SP Cohen","year":"2018","unstructured":"Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine Infusions for chronic pain from the American society of regional anesthesia and pain medicine, the American academy of pain medicine, and the American society of anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521\u201346. https:\/\/doi.org\/10.1097\/AAP.0000000000000808.","journal-title":"Reg Anesth Pain Med"},{"key":"649_CR25","doi-asserted-by":"publisher","first-page":"209705","DOI":"10.1016\/j.josat.2025.209705","volume":"175","author":"R Janssen-Aguilar","year":"2025","unstructured":"Janssen-Aguilar R, Meshkat S, Demchenko I, et al. Role of ketamine in the treatment of substance use disorders: a systematic review. J Subst Use Addict Treat. 2025;175:209705. https:\/\/doi.org\/10.1016\/j.josat.2025.209705.","journal-title":"J Subst Use Addict Treat"},{"key":"649_CR26","doi-asserted-by":"publisher","first-page":"1552084","DOI":"10.3389\/fpsyt.2025.1552084","volume":"16","author":"MR Shen","year":"2025","unstructured":"Shen MR, Campbell DE, Kopczynski A, et al. Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review. Front Psychiatry. 2025;16:1552084. https:\/\/doi.org\/10.3389\/fpsyt.2025.1552084. Published 2025 Apr 30.","journal-title":"Front Psychiatry"},{"issue":"15","key":"649_CR27","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1111\/bph.70018","volume":"182","author":"A Michael","year":"2025","unstructured":"Michael A, Onisiforou A, Georgiou P, et al. (2R, 6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement in mice. Br J Pharmacol. 2025;182(15):3428\u201351. https:\/\/doi.org\/10.1111\/bph.70018.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"649_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/ADM.0000000000001047","volume":"17","author":"C Grover","year":"2023","unstructured":"Grover C, Sturgill D, Goldman L. Post-acute withdrawal syndrome. J Addict Med. 2023;17(2):219\u201321. https:\/\/doi.org\/10.1097\/ADM.0000000000001047.","journal-title":"J Addict Med"},{"issue":"6","key":"649_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/cns.12099","volume":"19","author":"G Mion","year":"2013","unstructured":"Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370\u201380. https:\/\/doi.org\/10.1111\/cns.12099.","journal-title":"CNS Neurosci Ther"},{"issue":"9","key":"649_CR30","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","volume":"55","author":"MA Peltoniemi","year":"2016","unstructured":"Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059\u201377. https:\/\/doi.org\/10.1007\/s40262-016-0383-6.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"649_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0376-8716(95)01119-j","volume":"38","author":"KA Trujillo","year":"1995","unstructured":"Trujillo KA, Akil H. Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Depend. 1995;38(2):139\u201354. https:\/\/doi.org\/10.1016\/0376-8716(95)01119-j.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"649_CR32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","volume":"119","author":"A Gupta","year":"2011","unstructured":"Gupta A, Devi LA, Gomes I. Potentiation of \u03bc-opioid receptor-mediated signaling by ketamine. J Neurochem. 2011;119(2):294\u2013302. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07361.x.","journal-title":"J Neurochem"},{"issue":"3","key":"649_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/biom12030426","volume":"12","author":"Y Mizobuchi","year":"2022","unstructured":"Mizobuchi Y, Miyano K, Manabe S, et al. Ketamine improves desensitization of \u00b5-opioid receptors induced by repeated treatment with fentanyl but not with morphine. Biomolecules. 2022;12(3):426. https:\/\/doi.org\/10.3390\/biom12030426. Published 2022 Mar 10.","journal-title":"Biomolecules"},{"issue":"1","key":"649_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41398-024-02796-0","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang C, DiLeone RJ, Pittenger C, Duman RS. The endogenous opioid system in the medial prefrontal cortex mediates ketamine\u2019s antidepressant-like actions. Transl Psychiatry. 2024;14(1):90. https:\/\/doi.org\/10.1038\/s41398-024-02796-0. Published 2024 Feb 12.","journal-title":"Transl Psychiatry"},{"key":"649_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","volume":"1562","author":"F Pacheco Dda","year":"2014","unstructured":"Pacheco Dda F, Romero TR, Duarte ID. Central antinociception induced by ketamine is mediated by endogenous opioids and \u03bc- and \u03b4-opioid receptors. Brain Res. 2014;1562:69\u201375. https:\/\/doi.org\/10.1016\/j.brainres.2014.03.026.","journal-title":"Brain Res"},{"issue":"12","key":"649_CR36","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205\u201315. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18020138.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"649_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13063-025-08836-4","volume":"26","author":"A Mansoori","year":"2025","unstructured":"Mansoori A, Bazrafshan A, Ahmadi J, Mosavat SH. Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity. Trials. 2025;26(1):133. https:\/\/doi.org\/10.1186\/s13063-025-08836-4. Published 2025 Apr 17.","journal-title":"Trials"},{"issue":"8","key":"649_CR38","first-page":"625","volume":"42","author":"T Jovaisa","year":"2006","unstructured":"Jovaisa T, Laurinenas G, Vosylius S, Sipylaite J, Badaras R, Ivaskevicius J. Effects of ketamine on precipitated opiate withdrawal. Medicina (Kaunas). 2006;42(8):625\u201334.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"649_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/ADM.0000000000000929","volume":"16","author":"C Hailozian","year":"2022","unstructured":"Hailozian C, Luftig J, Liang A, et al. Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use. J Addict Med. 2022;16(4):483\u201387. https:\/\/doi.org\/10.1097\/ADM.0000000000000929.","journal-title":"J Addict Med"},{"issue":"4","key":"649_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/ADM.0000000000001151","volume":"17","author":"NJ Christian","year":"2023","unstructured":"Christian NJ, Butner JL, Evarts MS, Weimer MB. Precipitated opioid withdrawal treated with ketamine in a hospitalized patient: a case report. J Addict Med. 2023;17(4):488\u201390. https:\/\/doi.org\/10.1097\/ADM.0000000000001151.","journal-title":"J Addict Med"},{"key":"649_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1876386301104010001","volume":"4","author":"S Omoigui","year":"2011","unstructured":"Omoigui S, Hashmat F, Bernardo Z. Use of ketamine in ameliorating opioid withdrawal symptoms during an induction phase of Buprenorphine. Open Pain J. 2011;4:1\u20133.","journal-title":"Open Pain J"},{"issue":"1","key":"649_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13722-024-00494-2","volume":"19","author":"LA Grande","year":"2024","unstructured":"Grande LA, Hutch T, Jack K, et al. Ketamine-assisted buprenorphine initiation: a pilot case series. Addict Sci Clin Pract. 2024;19(1):60. https:\/\/doi.org\/10.1186\/s13722-024-00494-2. Published 2024 Aug 29.","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"649_CR43","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder [published correction appears in JAMA Netw Open. 2024 May 1; 7(5): e2419798. doi: 10.1001\/jamanetworkopen.2024.19798.]. JAMA Netw Open. 2020;3(2):e1920622. Published 2020 Feb 5. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"649_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/0269881120936909","volume":"35","author":"YL Zhou","year":"2021","unstructured":"Zhou YL, Liu WJ, Wang CY, et al. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. J Psychopharmacol. 2021;35(2):159\u201367. https:\/\/doi.org\/10.1177\/0269881120936909.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"649_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65\u201378. https:\/\/doi.org\/10.1016\/S2215-0366(17)30272-9.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"649_CR46","doi-asserted-by":"publisher","first-page":"e236108","DOI":"10.1001\/jamanetworkopen.2023.6108","volume":"6","author":"G D\u2019Onofrio","year":"2023","unstructured":"D\u2019Onofrio G, Hawk KF, Perrone J. Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl. JAMA Network Open. 2023;6(3):e236108. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.6108.","journal-title":"JAMA Network Open"},{"issue":"3","key":"649_CR47","doi-asserted-by":"publisher","first-page":"e231572","DOI":"10.1001\/jamanetworkopen.2023.1572","volume":"6","author":"H Snyder","year":"2023","unstructured":"Snyder H, Chau B, Kalmin MM, et al. High-dose buprenorphine initiation in the emergency department among patients using fentanyl and other opioids. JAMA Netw Open. 2023;6(3):e231572. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.1572. Published 2023 Mar 1.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"649_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001296","volume":"18","author":"S Wong","year":"2024","unstructured":"Wong S, Fabiano N, Webber D, Kleinman RA. High-dose buprenorphine initiation: a scoping review. J Addict Med. 2024;18(4):349\u201359. https:\/\/doi.org\/10.1097\/ADM.0000000000001296.","journal-title":"J Addict Med"},{"issue":"8","key":"649_CR49","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/bja\/53.8.805","volume":"53","author":"IS Grant","year":"1981","unstructured":"Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.M. and oral ketamine. Br J Anaesth. 1981;53(8):805\u201310. https:\/\/doi.org\/10.1093\/bja\/53.8.805.","journal-title":"Br J Anaesth"},{"key":"649_CR50","doi-asserted-by":"publisher","first-page":"1141980","DOI":"10.3389\/fpsyt.2023.1141980","volume":"14","author":"KE Dunn","year":"2023","unstructured":"Dunn KE, Bird HE, Bergeria CL, Ware OD, Strain EC, Huhn AS. Operational definition of precipitated opioid withdrawal. Front Psychiatry. 2023;14:1141980. https:\/\/doi.org\/10.3389\/fpsyt.2023.1141980. Published 2023 Apr 20.","journal-title":"Front Psychiatry"},{"key":"649_CR51","unstructured":"Grande L, Hutch T, Herring A. Ketamine to facilitate transition from fentanyl to buprenorphine: theory and application. Presented at: ASAM 54th Annual Conference. Washington DC: 2023 April 15."},{"issue":"7","key":"649_CR52","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/pme.12705","volume":"16","author":"TL Ahern","year":"2015","unstructured":"Ahern TL, Herring AA, Miller S, Frazee BW. Low-dose ketamine infusion for emergency department patients with severe Pain. Pain Med. 2015;16(7):1402\u201309. https:\/\/doi.org\/10.1111\/pme.12705.","journal-title":"Pain Med"},{"issue":"10","key":"649_CR53","doi-asserted-by":"publisher","first-page":"620","DOI":"10.12788\/jhm.3662","volume":"16","author":"RD Rothman","year":"2021","unstructured":"Rothman RD, Peter DJ, Harte BJ. Improving healthcare value: managing length of stay and Improving the hospital Medicine value proposition. J Hosp Med. 2021;16(10):620\u201322. https:\/\/doi.org\/10.12788\/jhm.3662.","journal-title":"J Hosp Med"},{"issue":"2","key":"649_CR54","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/ADM.0000000000001077","volume":"17","author":"C Wunsch","year":"2023","unstructured":"Wunsch C, Wightman R, Pratty C, et al. Thirty-day treatment continuation after audio-only buprenorphine telehealth initiation. J Addict Med. 2023;17(2):206\u201309. https:\/\/doi.org\/10.1097\/ADM.0000000000001077.","journal-title":"J Addict Med"},{"key":"649_CR55","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.dadr.2024.100227","volume":"11","author":"MJ Lynch","year":"2024","unstructured":"Lynch MJ, Vargas D, Winger ME, et al. A telemedicine bridge clinic improves access and reduces cost for opioid use disorder care. Drug Alcohol Depend Rep. 2024;11:100227. https:\/\/doi.org\/10.1016\/j.dadr.2024.100227. Published 2024 Mar 12.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"6","key":"649_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.psym.2018.07.006","volume":"59","author":"R Lauhan","year":"2018","unstructured":"Lauhan R, Hsu A, Alam A, Beizai K. Tianeptine Abuse and dependence: case report and literature review. Psychosomatics. 2018;59(6):547\u201353. https:\/\/doi.org\/10.1016\/j.psym.2018.07.006.","journal-title":"Psychosomatics"},{"issue":"1","key":"649_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13181-024-01053-6","volume":"21","author":"M Quadir","year":"2025","unstructured":"Quadir M, Rine NI, Badeti J, et al. Tianeptine exposures reported to United States poison centers, 2015-2023. J Med Toxicol. 2025;21(1):30\u201341. https:\/\/doi.org\/10.1007\/s13181-024-01053-6.","journal-title":"J Med Toxicol"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00649-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00649-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00649-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:06:56Z","timestamp":1781633216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00649-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00649-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"19 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal consent was obtained from all patients. De-identified data were maintained to determine the success of the quality improvement exercise. The University of South Alabama Institutional Review Board determined that this data analysis was exempt from IRB review as it did not meet the federal definition of human subjects research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}